Compare IRON & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | RHI |
|---|---|---|
| Founded | 2017 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | IRON | RHI |
|---|---|---|
| Price | $94.29 | $26.95 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 12 | 7 |
| Target Price | ★ $108.83 | $40.00 |
| AVG Volume (30 Days) | 533.0K | ★ 2.5M |
| Earning Date | 11-06-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 8.81% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.54 |
| Revenue | N/A | ★ $5,458,499,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.14 |
| P/E Ratio | ★ N/A | $17.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.82 | $25.22 |
| 52 Week High | $97.12 | $78.41 |
| Indicator | IRON | RHI |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 43.80 |
| Support Level | $87.18 | $26.00 |
| Resistance Level | $96.18 | $28.01 |
| Average True Range (ATR) | 3.94 | 0.90 |
| MACD | -0.32 | 0.20 |
| Stochastic Oscillator | 56.25 | 60.87 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.